Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 5, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Cisplatin-conjugated Gelpart: initial study in vitro.

Shinichi Ohta1, Norihisa Nitta, Akinaga Sonoda

  • 1Department of Radiology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu City, Shiga, Japan.

Hepatology Research : the Official Journal of the Japan Society of Hepatology
|May 24, 2008
PubMed
Summary

Researchers developed cisplatin-conjugated Gelpart, a novel embolic agent for hepatocellular carcinoma. This innovative material demonstrates effective cisplatin bonding and sustained drug release in vitro, paving the way for advanced cancer therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility and efficacy of a thermal ablation device utilizing a nitinol-based coil.

Acta radiologica (Stockholm, Sweden : 1987)·2025
Same author

An update on the impact of bystander cardiopulmonary resuscitation on favorable neurological outcomes of patients with out-of-hospital cardiac arrest accounting for effect modification by witnessed arrest: a post hoc analysis of the SOS-KANTO 2017 study.

Resuscitation plus·2025
Same author

Endovascular treatment for ureterorectal-arterial fistula and external iliac artery stenosis caused by recurrent endometrial cancer invasion: A case report.

Radiology case reports·2025
Same author

Computed Tomography Imaging of Acute Mesenteric Ischemia for Interventional Radiology.

Interventional radiology (Higashimatsuyama-shi (Japan)·2025
Same author

A Bizarre Complication of Lymphangiography for Chylothorax: Cardiac Tamponade Due to Chylopericardium.

Cardiovascular and interventional radiology·2025
Same author

Veillonella orientalis sp. nov., an anaerobic Gram-stain-negaitve coccus isolated from saliva of a Thai child.

Anaerobe·2024

Area of Science:

  • Biomaterials Science
  • Oncology
  • Drug Delivery Systems

Background:

  • Gelpart, a gelatin-based embolic agent, is used for hepatocellular carcinoma treatment in Japan.
  • Developing targeted drug delivery systems is crucial for improving cancer therapy efficacy and reducing side effects.

Purpose of the Study:

  • To create cisplatin-conjugated Gelpart.
  • To verify the bonding capability of cisplatin to Gelpart.
  • To evaluate the in vitro release of cisplatin from the conjugated Gelpart.

Main Methods:

  • Gelpart was immersed in a cisplatin solution for conjugation.
  • Uncombined cisplatin was removed through washing and centrifugation.
  • Platinum concentrations were analyzed in washed and unwashed Gelpart.

More Related Videos

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

Related Experiment Videos

Last Updated: Jul 5, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

  • In vitro release studies were conducted in phosphate-buffered saline at 38°C over 24 hours.

    • Main Results:

    • Washed Gelpart showed a platinum concentration of 6396.5 ± 14.8 µg/g.
    • Unwashed Gelpart exhibited a higher platinum concentration of 9563.5 ± 101.1 µg/g.
    • Washed Gelpart demonstrated sustained cisplatin release, reaching approximately 12.0% over 24 hours, while unwashed Gelpart released up to 60.9%.

    Conclusions:

    • Gelpart possesses a strong bonding capability for cisplatin.
    • Cisplatin-conjugated Gelpart exhibits sustained release properties.
    • This conjugate holds potential as a simple embolic agent integrated with drug delivery capabilities for cancer treatment.